Results for lenalidomiid translation from Estonian to English

lenalidomiid
lenalidomide

revlimid lenalidomiid
revlimid lenalidomide

lenalidomiid ja deksametasoon
lenalidomide and dexamethasone

toimeaine on lenalidomiid.
the active substance is lenalidomide.

lenalidomiid kahjustab loodet.
lenalidomide is expected to be harmful to the unborn child.

lenalidomiid (25 mg), suukaudne
lenalidomide (25 mg) oral

kyprolis, lenalidomiid ja deksametasoon
kyprolis, lenalidomide, and dexamethasone

empliciti + lenalidomiid ja deksametasoon
empliciti + lenalidomide and dexamethasone

revlimid 10 mg kõvakapslid lenalidomiid
revlimid 10 mg hard capsules lenalidomide

lenalidomiid ei ole ensüümide indutseerija.
lenalidomide is not an enzyme inducer.

lenalidomiid on struktuurilt lähedane talidomiidile.
lenalidomide is structurally related to thalidomide.

lenalidomiid eritub peamiselt neerude kaudu.
lenalidomide is substantially excreted by the kidney.

lenalidomiid on sündimata lapsele eeldatavalt kahjulik.
lenalidomide is expected to be harmful to an unborn child.

neerukahjustus lenalidomiid eritub peamiselt neerude kaudu.
renal impairment lenalidomide is substantially excreted by the kidney.

revlimid 10 mg kõvakapslid: • toimeaine on lenalidomiid.
revlimid 10 mg hard capsules: • the active substance is lenalidomide.

revlimidis toimeainena sisalduv lenalidomiid on immuunsust moduleeriv aine.
the active substance in revlimid, lenalidomide, is an immunomodulating agent.

hoiatus raseduse korral lenalidomiid on struktuuri poolest sarnane talidomiidiga.
pregnancy warning lenalidomide is structurally related to thalidomide.

lenalidomiid kombinatsioonis deksametasooniga patsientidel, kellele tüviraku siirdamine ei ole näidustatud
lenalidomide in combination with dexamethasone in patients who are not candidates for stem cell transplantation

lenalidomiidi kasutamisel raseduse ajal avaldab lenalidomiid inimestele eeldatavalt teratogeenset toimet.
if lenalidomide is taken during pregnancy, a teratogenic effect of lenalidomide in humans is expected.

lenalidomiid metaboliseerub vähe, sest 82% annusest eritub uriiniga muutumatul kujul.
lenalidomide is poorly metabolized as 82% of the dose is excreted unchanged in urine.